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Abstract
Objective: To assess predictors of well-differentiated thyroid cancer (WDTC) persistence/recurrence.
Design: This was a retrospective chart review of thyroid carcinoma patients seen 1979-2007 in a Boston,
Massachusetts-area multispecialty group. Of 1,025 patients, 431 met eligibility criteria. Cox proportional hazards
models were used to assess predictors (gender, age, ethnicity, tumor size, surgical histology) of WDTC persistence/
recurrence (elevated thyroglobulin levels with negative thyroglobulin-antibodies; or positive imaging). Local
extension of disease and lymph node involvement could not be assessed.
Results: Mean age at initial surgery (n = 431, 74% women, 79% Caucasian) was 45.8 ± 13.5(SD) years. Mean tumor
(papillary, 91%; follicular, 5%; Hurthle cell, 2%; ≥1 type, 2%) size was 2.5 ± 1.6(SD) cm. Most tumors were unifocal
(57%) and ≥1 cm (89%). Over 2,600 person-years of follow-up, persistence/recurrence occurred in 52 patients (12%)
4.3 years (median; range 0.2-23.2 years) after surgery. Gender, ethnicity, tumor size, multifocality, and histology were
not predictive of persistence/recurrence, while older age was predictive in some models.
Conclusions: In WDTC patients treated by total and near total thyroidectomy and radioiodine and analyzed
without consideration of local, locoregional, and distant extent of disease, neither size of tumor nor male gender
contribute to disease persistence/recurrence. Age at diagnosis seems to have some positive prognostic value even
if only patients older than 21 years at diagnosis are considered. Due to the rare occurrence of follicular (also
oxyphilic) histotype, this conclusion refers mainly to patients with papillary thyroid cancer.
Introduction
Many post-operative scoring systems have been pro-
posed to predict outcomes of well-differentiated thyroid
cancer (WDTC). The AMES criteria were developed in
the late 1980s and examine age, distant metastasis,
tumor extent, and tumor size to predict prognosis in
patients with differentiated thyroid cancer [1]. Both the
AGES system, which scores age, tumor size, histologic
grade, tumor extent, and distant metastasis [2] and the
MACIS system, which scores distant metastasis, age,
completeness of primary tumor resection, local invasion,
and tumor size [3] were established by Hay et al. in the
late 1980s and early 1990s as prognostic scoring systems
for patients with papillary thyroid cancer. In 1998, the
Thyroid Cancer Treatment Cooperative Study Registry
Group validated a clinicopathologic staging utilizing age
at diagnosis, tumor histology, tumor size, intrathyroidal
multifocality, extraglandular invasion, metastases, and
tumor differentiation [4]. Finally, the TNM scoring sys-
tem, which utilizes tumor size, lymph node involvement,
and distant metastasis, was developed by the American
Joint Committee on Cancer to provide a staging system
for all malignancies, including differentiated thyroid
cancers [5].
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monly used as a marker of thyroid tissue persistence/
recurrence after near-total thyroidectomy in patients
with negative Tg-antibody titers, with recombinant
human thyroid stimulating hormone (rhTSH)-stimulated
Tg levels >2.5 ng/mL as the optimal level for future
recurrence [6]. It may remain elevated for several weeks
or months after surgery, and its sensitivity is improved
with post-operative remnant radioiodine ablation [7].
Although no single scoring system has been clearly
superior, in part due to the differences used in the
weighting and combinations of independent predictors,
distant metastases, age of the patient, and extent of the
tumor seem to be the most consistent predictors of per-
sistent or recurrent disease [8].
Several retrospective analyses have assessed outcomes
of low-risk thyroid cancer using these and other factors.
In what eventually became the Ohio State University
staging system for papillary or follicular thyroid carcino-
mas, Mazzaferri and Jhiang reported that in 1,355
patients with well-differentiated tumors ≥1.5 cm with or
without local or lymph node spread followed over 40
years, near-total thyroidectomy followed by radioiodine
ablation and TSH suppression therapy improves out-
comes [9]. A review summarizing guidelines by the
American Thyroid Association, which have recently
been revised [8], the European Thyroid Association, and
other recent literature has recommended that total or
near-total thyroidectomy followed by remnant ablation
is acceptable for those with low-risk papillary thyroid
cancer, although surgery alone may be sufficient for
some tumors removed incidentally during surgery for
benign disease, in the absence of other concerning his-
tory [10]. Ongoing research is needed to help clarify the
factors which best predict persistence or recurrence of
well-differentiated thyroid cancer to guide short-term
and long-term management.
The objective of this study was to test the hypothesis
that certain patient-associated or tumor-associated factors
predict well-differentiated thyroid cancer persistence or
recurrence in a Boston, Massachusetts-area cohort of
well-differentiated thyroid cancer patients treated with
thyroidectomy and radioiodine over a 28-year period.
Methods
Study sample
A retrospective chart review was conducted of patients
with well-differentiated thyroid cancer evaluated at all
sites of a large Boston, Massachusetts-area multispecialty
group practice (Harvard Vanguard Medical Associates,
HVMA) between 1979 and 2007. Patients with ICD-9
code 193 (thyroid carcinoma) had been identified for a
previously-created health quality assurance database at all
HVMA sites between January 1979 and May 2007. Of
the 1,025 individuals in the preexisting database, 65 were
incorrectly coded as having thyroid cancer. Of the
remaining 960 potentially eligible patients, 431 (45%) met
study criteria and were enrolled in the study.
Inclusion criteria were: 1) at least age 21 at the time of
thyroid surgery, 2) history of total or near-total thyroi-
dectomy, 3) diagnosis of papillary, follicular, or Hurthle
cell carcinoma by surgical pathology, 3) use of radioio-
dine ablation post-operatively, and 4) follow-up manage-
ment within HVMA that included at least one serum
thyroglobulin measurement, and/or imaging study by
either radioiodine scan, neck ultrasonography, CT, MRI,
or FDG-PET. Local extension of disease and lymph node
involvement were not included due to the absence of
t h e s ed a t ai nm a n yp a t i e n t sw h oh a dt h e i rt h y r o i ds u r -
gery by non-HVMA providers within the cohort. Exclu-
sion criteria were: 1) medullary thyroid cancer, 2)
anaplastic thyroid cancer, 3) incorrectly-coded ICD-9
diagnosis of thyroid cancer, 4) no documentation of thyr-
oid cancer pathology, 5) positive thyroglobulin antibody
titers (which make thyroglobulin results uninterpretable)
without follow-up imaging, and 6) a positive thyroglobu-
lin level within 6 months of thyroid surgery as the last
known status. The date of the thyroid surgery was the
entry point for the study. The protocol was approved by
the Harvard Vanguard Institutional Review Board.
Assessment of WDTC persistence or recurrence
Various factors assessing patient demographics and
tumor characteristics were grouped to assess their pre-
dictive effects on WDTC persistence or recurrence.
Gender, race, and age in years at thyroid surgery com-
prised the patient-associated factors. Tumor size in cen-
timeters and histologic tumor type (e.g. papillary,
follicular, Hurthle, or a combination of these) by surgi-
cal pathology report comprised the tumor-associated
factors. Local extension of disease and lymph node
involvement could not be assessed.
Based on the chart review, the persistence or recur-
rence of well-differentiated thyroid cancer, defined as the
primary outcome, was determined at the final time point
for which their status was known. For the purposes of
this study, thyroid cancer persistence or recurrence were
considered identical. Recurrence or persistence of tumor,
following total thyroidectomy and radioiodine ablation,
was defined as serum thyroglobulin levels greater than
0.5 μg/L (unstimulated) or >2 μg/L (following rhTSH
stimulation or thyroid hormone withdrawal) with nega-
tive thyroglobulin antibodies [8]. Thyroglobulin measure-
ments were performed using a chemiluminescence
immunoassay (Immulite 2000, Diagnostics Products Cor-
poration). Because an earlier chemiluminescence immu-
noassay assay used at HVMA had a lower limit of
detection of 0.9 μg/L, an unstimulated thyroglobulin level
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rence in individuals whose most recent serum thyroglo-
bulin was obtained prior to the assay change. Imaging
modalities also used to define recurrence or persistence
were whole body radioiodine scan with any positive
uptake, a positive PET scan, and/or a positive neck ultra-
sound scan with confirmatory fine needle aspiration
biopsy or surgical pathology of tissue sampled from the
suspected site(s) of recurrence.
Statistical analysis
This study was a retrospective chart review of a preex-
isting database, and therefore it was not powered for the
primary outcome. Descriptive information is presented
as frequencies and percentages for categorical variables
and as means ± SD for continuous variables. Age was
analyzed as a continuous variable in the primary analysis
and dichotomized at 45 years for some of the secondary
analyses in the Cox proportional hazard regression mod-
els. Tumor size was dichotomized at <1 cm and ≥ 1 cm.
Secondary analyses included additional stratifications of
tumor size at <1.5 cm and ≥ 1.5 cm, <2 cm and ≥ 2 cm,
<3 cm and ≥ 3 cm, <4 cm and ≥ 4 cm; tumor size was
also analyzed as a continuous measure. Differences
between categorical variables were analyzed using the
Chi-square test. Among subjects in whom either the
month or date of thyroid surgery was undocumented
(but for whom at least the year was recorded), the miss-
i n gm o n t hw a sa s s i g n e da sJ u n ea n dt h ed a t ea st h e
15th of the month. Study entry was the date of surgery.
Follow-up was accrued until the first occurrence of the
primary outcome or the date of last contact.
Independent predictors were organized into two con-
ceptual groups (patient-associated and tumor-associated
predictors). Separately and together in a comprehensive
model, Cox proportional hazards regression models and
the appropriate tests for verifying the proportional
hazards assumption were constructed to determine the
associations of the independent predictors with the time
to tumor persistence or recurrence. Person-time was
computed to the first recurrence and was censored at the
date of last contact. Models were adjusted for sex, race,
and subjects’ age at surgery. Potential confounders were
assessed for as appropriate. A subset analysis of the two
conceptual groups, again separately and together in a
comprehensive model, was also performed excluding
patients who had thyroid surgery prior to the start of the
electronic database to minimize any selection bias due to
subjects who may have died (from WDTC or otherwise)
prior to the start of the study period.
P-values <0.05 were considered statistically significant.
All statistical analyses were performed using SAS ver-
sion 9.1 (SAS Institute, Cary, NC).
Results
From the database of 1,025 patients, 431 met entry
criteria. The 594 excluded patients were comprised of
220 patients who did not have a total or near-total thyr-
oidectomy or postoperative radioiodine ablation (groups
in whom Tg levels are difficult to interpret), 152 patients
who had no laboratory results or imaging studies for
thyroid cancer at least 6 months after thyroid surgery
internally at HVMA, 68 patients who had benign thyroid
disease or a non-thyroidal cancer, 52 patients who had
no surgical pathology results in the HVMA database, 46
patients without a recorded year of surgery, 27 patients
who were under age 21 at the time of surgery, 15 patients
who had medullary thyroid carcinoma, 5 patients who
had anaplastic thyroid carcinoma, 8 patients who had
positive Tg-antibody titers without follow-up imaging,
and 2 patients who were miscoded with an incorrect
medical record number. Descriptive statistics of the study
population are given in Table 1.
Survival analysis
There were 2,600 total person-years of follow-up; 52 sub-
jects (12%) had WDTC persistence/recurrence (Figure 1)
at a median of 4.3 years (range 0.2-26.2; mean 6.1 ± 5.6
years) after thyroid surgery.
Multivariate analyses of the full dataset
The Cox regression model of patient-associated predictors
of disease persistence or recurrence was significant (p =
0.02), while that of tumor-associated predictors was not
(p = 0.80). In a multivariable analysis (with sex, race, age
at diagnosis, number of tumor foci, tumor size, and tumor
histology as independent predictors), the comprehensive
Cox regression model was predictive (p = 0.04) of disease
persistence or recurrence, including older age as a signifi-
cant independent predictor (p = 0.02). The comprehensive
models predicting disease persistence or recurrence were
also significant when tumor size was categorized into
4 groups (<1 cm, 1 to <2 cm, 2 to <3 cm, and ≥3 cm) (p =
0.04); dichotomized at 1.5 cm (p = 0.04), 2 cm (p = 0.04),
3 cm (p = 0.04), or 4 cm (p = 0.04); and when analyzed as
a continuous measure (p = 0.04). Greater age as a continu-
ous variable was weakly predictive of tumor persistence or
recurrence, although this was not consistent across all
models. A summary of the Cox regression models is
presented in Table 2.
Multivariate analyses after excluding subjects with
thyroid surgery prior to 1979
A subset analysis was also performed to include only
patients who had surgery after the start of the study per-
iod (January 1979) (n = 415). The Cox regression model
of patient-associated factors was predictive (p = 0.03),
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predictor (HR 0.49; 95% CI, 0.25 to 0.95; p = 0.03). The
regression model of tumor-associated factors was not
predictive (p = 0.85). Similarly, using this restricted
cohort, the multivariable analysis (with sex, race, age at
diagnosis, number of tumors, tumor size, and tumor his-
tology as independent predictors) were not predictive of
disease persistence or recurrence (p = 0.06).
Discussion
This retrospective analysis suggests that specific factors
may predict disease persistence or recurrence in patients
with well-differentiated thyroid carcinoma. The Ameri-
can Thyroid Association has recommended that follow-
up treatment varies according to a patient’sr i s kf o r
recurrence [8], yet management, including the extent of
surgery, necessity of post-operative ablative radioiodine,
and degree of thyroid hormone suppression, has been
controversial and practices are not uniform among
clinicians.
An analysis of all patients with a history of WDTC in
our database, regardless of the extent of surgery or use
of radioiodine (n = 651), resulted in a persistence/recur-
rence rate of 20% (data not shown). While this is vir-
tually identical to what was observed in a similar cohort
assessed over 30 years by Mazzaferri and Jhiang (21%)
[9], by restricting our analyses to patients who under-
went a total or near-total thyroidectomy and radioiodine
therapy, the rate dropped to 12%. Our Cox regression
model of patient-associated factors and the global model
were predictive of well-differentiated thyroid cancer per-
sistence or recurrence, although the regression model of
tumor-associated factors was not. Greater age as a con-
tinuous variable was a weakly predictive factor, but this
was not consistent across all models.
Our analysis included only those who were alive at
follow-up, and therefore loss of follow-up due to death
[both disease-specific and all-cause mortality) was not
ascertained. In addition, some subjects excluded due to
the absence of thyroglobulin values or an imaging study
within the HVMA database were managed by non-
HVMA providers and were not available for this analy-
sis. Finally, the unique demographics and socioeconomic
status of this study population (e.g. predominantly Cau-
casian) may limit generalizability to other populations
managed by clinicians experienced in thyroid cancer
follow-up.
It is difficult to compare the relative predictive abilities
of different models or staging systems, as the compo-
nents in each are not uniform. Palme et al. reported
that male sex, advanced initial stage, and presence of
extrathyroidal spread were independent predictors of
multiple recurrences of well-differentiated thyroid can-
cer [11]. In a recent retrospective review of papillary
microcarcinoma (≤1 cm), Mercante et al. found that
capsular invasion, extrathyroidal tumor extension, and
neck lymph node metastasis at presentation were the
only independent risk factors for the persistence or
recurrence of disease [12]. In contrast to these and
other studies [13,14], many of the subjects in our study
received their surgery at a non-HVMA site, and thus,
information regarding extrathyroidal spread was not
codified in a uniform manner and could not be analyzed
in our cohort. The inability to capture this information
may have introduced a misclassification bias of patients’
disease burden, thereby altering our findings. The use of
a <1 cm cutoff for tumor size in our study (as compared
to ≤1 cm) may also limit direct comparison of our
Table 1 Subject demographics, tumor characteristics, and
management factors
n
Gender
Male 110 (26%)
Female 321 (74%)
Race
Caucasian 280 (79%)
Black 34 (10%)
Hispanic 7 (2%)
Asian/Pacific Islander 12 (3%)
Other 21 (6%)
Age (years) at surgery 45.8 (mean) ± 13.5 (SD)
Tumor size (cm) 2.5 (mean) ± 1.6 (SD) (2.2 (median);
range, 0.1-10.0
Tumor size
<1 cm 39 (11%)
≥1 cm 329 (89%)
Tumor histology
Papillary (PTC) 388 (91%)
Follicular (FTC) 20 (5%)
Both PTC and FTC 6 (1%)
Hurthle cell carcinoma (HCC) 9 (2%)
Both PTC and HCC 4 (1%)
Number of tumor foci
1 213 (57%)
≥2 161 (43%)
Thyroid cancer recurrence or
persistence
Yes 52 (12%)
No 379 (88%)
Positive disease on follow-up
imaging
Yes 33 (9%)
No 334 (91%)
Years after surgery at
recurrence
6.1 (mean) ± 5.6 (SD) 4.3 (median) 0.2-
23.2 (range)
* Total n for each descriptor may not equal 431 due to missing data, and
total percentages may not equal 100 due to rounding.
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study these specific questions, it was recently reported
that recurrence of papillary and follicular thyroid cancer
in the first year following thyroid surgery predicts a
worse outcome [13], and patients with micropapillary
multifocal thyroid cancer have a reduced rate of recur-
rence following more complete thyroid surgery [15].
The differences between the variables analyzed in this
study and those of other investigators do not allow for
direct comparison of the predictive models.
There are several strengths of this study, which speci-
fically studied only patients who underwent a total
or near-total thyroidectomy and radioiodine ablation
to evaluate laboratory and imaging markers of WDTC
persistence/recurrence. All sites of a large Boston, Mas-
sachusetts-area multispecialty group practice were
included, and there was a relatively long period of fol-
low-up of over 28 years. Many subjects contributed sub-
stantial person-time toward the primary outcome.
Furthermore, this group practice, which consists of
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Figure 1 Kaplan-Meier curve of differentiated thyroid cancer persistence or recurrence (full dataset).
Table 2 Individual and comprehensive Cox regression models predicting the persistence or recurrence of WDTC
n number with persistence
or recurrence
hazard ratio 95% CI p
Patient-associated factors 354 44 0.02
Gender 0.54 0.28, 1.03 0.06
Age 0.97 0.93, 1.01 0.09
Ethnicity 1.17 0.96, 1.42 0.12
Interaction of age and time to persistence or recurrence 1.03 1.01, 1.06 0.01
Tumor-associated factors 368 39 0.80
Size (dichotomized) 0.81 0.28, 2.32 0.70
Number of foci 0.88 0.61, 1.27 0.48
Histology 0.89 0.53, 1.49 0.66
Comprehensive model 309 37 0.04
Gender 0.57 0.27, 1.21 0.14
Age 0.95 0.90, 0.99 0.02
Ethnicity 1.17 0.96, 1.44 0.13
Tumor size 0.57 0.19, 1.68 0.31
Number of foci 0.94 0.65, 1.36 0.74
Histology 0.68 0.32, 1.44 0.31
Interaction of age and time to recurrence or persistence 1.04 1.02, 1.07 <0.01
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the late 1970s, thus permitting an easily extractable and
long-term comprehensive assessment of patients fol-
lowed within it with WDTC.
The findings of this study do not confirm previously
published data that male gender and larger tumors have
a worse prognosis for WDTC persistence/recurrence.
We urge the establishment of a comprehensive national
registry, created through linkage with electronic health
record systems, that would uniformly capture informa-
tion regarding these and other factors for the long-term
monitoring of WDTC outcomes.
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